VizMark

VizMark is a medical technology company specializing in advanced imaging solutions for women's health, with a primary focus on breast cancer care. The company's flagship product, VM1, is a non-metallic, allergy-free visual tumor marker designed for permanent implantation following a biopsy. Unlike traditional metallic markers, VM1 provides artifact-free visibility across all major imaging modalities, including MRI, mammography, CT, and ultrasound. This technology addresses a critical clinical need by ensuring precise tumor localization and long-term monitoring without the imaging interference common in dense breast tissue. Founded by Dr. Michael T. Nelson, a Professor of Radiology, VizMark received FDA 510(k) clearance for VM1 in early 2026 and is currently focused on its commercial rollout in the United States.